Wilmington, NC, 13 May 2020 – Catalyst Clinical Research, a clinical development and global resourcing organization headquartered in Wilmington, NC, recently announced the hiring of Melissa Church as Chief Strategy Officer. Church will be leading the Marketing, Business Development and Commercial Operations functions in addition to driving corporate strategy from ideation through to execution.
Bringing to Catalyst more than 25 years of sales, operations, and strategy development experience, Church has primarily supported organizations within the clinical research, healthcare, and technology industries. She received a B.A. in Mass Communication from the University of North Carolina at Asheville and started her professional career in the CRO industry. Throughout her career, she worked for ClinTrials Research, Consella Group and, PPD. Most recently, she served as Vice President of Growth Operations first in Optum and then UnitedHealthcare Community & State, both part of UnitedHealth Group.
“I am excited to return to the clinical research industry and join the great team at Catalyst,” says Ms. Church. “It is a wonderful company at a really exciting point in its journey. Catalyst is on the cutting edge of delivering technology-driven, oncology-focused full-service trials and clinical, safety, and biometric resourcing solutions across all therapeutic areas.”
Catalyst CEO, Nick Dyer, states: “We are delighted to have Melissa join us at Catalyst. Her passion for, and track record in driving innovative solutions, and aligning those to customer needs is a welcome addition for the Catalyst leadership team.”
A North Carolina native, Church currently resides in Wilmington where she will operate out of the company headquarters.
About Catalyst
Catalyst is a clinical development organization providing highly customizable clinical research solutions to the global biopharmaceutical industry. With offices in the US and EU, the company provides global resourcing solutions, functional and full-service managed solutions, the latter with a focus on oncology therapeutics. Catalyst’s service model is built from more than a decade of listening to customers, devising customer-centric solutions and helping them drive breakthrough clinical development studies leveraging Catalyst’s expert teams and innovative technologies.
Catalyst is a portfolio company of NovaQuest Capital Management, LLC, a leading healthcare and life sciences investment firm.
